West Branch Capital’s ImmunityBio IBRX Stock Holding History

West Branch Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.57K	Hold	750	–	–	﹤0.01%	261
2026 Q1	$5.75K	Buy	+750	New	+$5.13K	﹤0.01%	265

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

West Branch Capital's IBRX Position: Q2 2026 in Review

West Branch Capital held its ImmunityBio (IBRX) position steady in Q2 2026 at 750 shares worth $6.57K. The position accounts for ﹤0.01% of the portfolio, ranked #261.

West Branch Capital first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

West Branch Capital held 750 shares of ImmunityBio worth $6.57K as of Q2 2026.
West Branch Capital left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of West Branch Capital's portfolio in Q2 2026, its #261 holding.
West Branch Capital first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on West Branch Capital's 13F filing for Q2 2026, filed 10 Jul 2026.